1. Home
  2. PRTC vs UPB Comparison

PRTC vs UPB Comparison

Compare PRTC & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • UPB
  • Stock Information
  • Founded
  • PRTC 2015
  • UPB 2021
  • Country
  • PRTC United States
  • UPB United States
  • Employees
  • PRTC N/A
  • UPB N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • UPB
  • Sector
  • PRTC Health Care
  • UPB
  • Exchange
  • PRTC Nasdaq
  • UPB NYSE
  • Market Cap
  • PRTC 402.3M
  • UPB 402.8M
  • IPO Year
  • PRTC N/A
  • UPB 2024
  • Fundamental
  • Price
  • PRTC $16.74
  • UPB $8.78
  • Analyst Decision
  • PRTC Buy
  • UPB Strong Buy
  • Analyst Count
  • PRTC 1
  • UPB 4
  • Target Price
  • PRTC $45.00
  • UPB $56.50
  • AVG Volume (30 Days)
  • PRTC 11.0K
  • UPB 305.5K
  • Earning Date
  • PRTC 04-28-2025
  • UPB 05-14-2025
  • Dividend Yield
  • PRTC N/A
  • UPB N/A
  • EPS Growth
  • PRTC N/A
  • UPB N/A
  • EPS
  • PRTC N/A
  • UPB N/A
  • Revenue
  • PRTC $468,000.00
  • UPB $2,370,000.00
  • Revenue This Year
  • PRTC N/A
  • UPB N/A
  • Revenue Next Year
  • PRTC $160.00
  • UPB $0.99
  • P/E Ratio
  • PRTC N/A
  • UPB N/A
  • Revenue Growth
  • PRTC N/A
  • UPB N/A
  • 52 Week Low
  • PRTC $13.30
  • UPB $5.14
  • 52 Week High
  • PRTC $32.98
  • UPB $29.46
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 47.62
  • UPB N/A
  • Support Level
  • PRTC $13.30
  • UPB N/A
  • Resistance Level
  • PRTC $16.75
  • UPB N/A
  • Average True Range (ATR)
  • PRTC 0.98
  • UPB 0.00
  • MACD
  • PRTC -0.03
  • UPB 0.00
  • Stochastic Oscillator
  • PRTC 51.39
  • UPB 0.00

About PRTC PureTech Health plc

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

About UPB UPSTREAM BIO INC

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.

Share on Social Networks: